The U.S. FDA hasn’t taken up criminal justice as a sideline, but it did just clear Sonio Suspect. Far from a social miscreant, Suspect improves detection of fetal anomalies by 22 points by automatically detecting multiple types of abnormal findings and allows for detection as early as 11 weeks of gestation.

The latest patenting from Canan Dagdeviren seeks protection for their wearable, conformable ultrasound breast patch that enables standardized and reproducible image acquisition over the entire breast with less reliance on operator training and applied transducer compression.

Dongkook Life Science Co. Ltd. (DKLS) priced a ₩18 billion (US$12.5 million) IPO on the Korea Exchange as South Korea’s first med-tech listing of the year.

Germitec SA raised $30 million in a series B financing round to bring Chronos, its chemical-free, ultraviolet-C (UV-C)-based disinfection system for ultrasound probes, to the U.S. market.

A recent patent application from Laleh Rad, associate professor of Biomedical Engineering and Radiology at Northwestern University, describes the use of machine learning for real-time risk assessment of magnetic resonance imaging in patients with conductive implants for whom tissue heating from radiofrequency excitation fields remains a major concern.

Neko Health AB raised $260 million in its series B funding round to expand the reach of its artificial intelligence (AI)-driven full body scanning technology to meet growing demand. The fund raise comes amid an increasing shift in behaviors towards more preventative measures in health care in a bid to remove the risk of developing chronic diseases.

Continuing a spate of beginning-of-the-year guidance, the U.S. FDA released a draft guidance on developing drugs for optical imaging.

Positrigo AG is raising $10 million for production and commercialization of its Neurolf brain positron emission tomography system in the U.S. The system hepls to diagnose Alzheimer’s disease. With drugs such as Leqembi and Kisunla gaining U.S. FDA approval to treat the devastating neurological condition, the company is seeing increasing demand for its system, Neurolf CEO and co-founder Jannis Fischer, told BioWorld.

On the heels of U.S. FDA approval for Neurophet Aqua, an updated version of its artificial intelligence (AI)-based magnetic resonance imaging analysis software for the brain, Neurophet Inc. is preparing for an IPO in 2025 and expansion into U.S. and European markets.

Hyperfine Inc. gained CE mark approval for the latest generation of its artificial intelligence-powered software for its Swoop portable magnetic resonance imaging system, under the European Medical Device Regulation.